2021
DOI: 10.3390/cancers13225650
|View full text |Cite
|
Sign up to set email alerts
|

Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles

Abstract: Microtubule-targeting agents (MTAs) represent one of the most successful first-line therapies prescribed for cancer treatment. They interfere with microtubule (MT) dynamics by either stabilizing or destabilizing MTs, and in culture, they are believed to kill cells via apoptosis after eliciting mitotic arrest, among other mechanisms. This classical view of MTA therapies persisted for many years. However, the limited success of drugs specifically targeting mitotic proteins, and the slow growing rate of most huma… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
68
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 90 publications
(69 citation statements)
references
References 254 publications
(287 reference statements)
1
68
0
Order By: Relevance
“…If YK-4-279 and vincristine both target MTs, how can synergy between these agents be explained? Distinct chemical families target MTs through several different binding pockets ( Florian and Mitchison, 2016 ; Wordeman and Vicente, 2021 ). We hypothesized that synergy between TK216 and vincristine could be explained if these agents acted on distinct MT binding pockets.…”
Section: Resultsmentioning
confidence: 99%
“…If YK-4-279 and vincristine both target MTs, how can synergy between these agents be explained? Distinct chemical families target MTs through several different binding pockets ( Florian and Mitchison, 2016 ; Wordeman and Vicente, 2021 ). We hypothesized that synergy between TK216 and vincristine could be explained if these agents acted on distinct MT binding pockets.…”
Section: Resultsmentioning
confidence: 99%
“…In recent years, advancing insights into the mechanisms of cardiovascular dysfunction have focused on the role of the microtubule network. Microtubule-targeting drugs, which interfere with microtubule dynamics, are one of the most successful first-line cancer therapies ( Wordeman and Vicente, 2021 ). However, systemic administration provokes a range of negative side effects on other systems ( Miltenburg and Boogerd, 2014 ).…”
Section: Introductionmentioning
confidence: 99%
“…There are more than 350 unique compounds in the taxoid class, categorized by their structural differences [1]. Each group within the taxoid diterpenoid class differs in polarity and pharmaceutical properties, particularly in biological activity [2,3]. Taxol was the first-ever drug used against cancer.…”
Section: Introductionmentioning
confidence: 99%